Patents by Inventor Michael Patrick Akers
Michael Patrick Akers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11872266Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.Type: GrantFiled: September 17, 2021Date of Patent: January 16, 2024Assignee: Eli Lilly and CompanyInventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
-
Publication number: 20220072105Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.Type: ApplicationFiled: September 17, 2021Publication date: March 10, 2022Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schutte, Ranajoy Majumdar
-
Patent number: 11123406Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.Type: GrantFiled: May 14, 2018Date of Patent: September 21, 2021Assignee: Eli Lilly and CompanyInventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
-
Publication number: 20210169988Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.Type: ApplicationFiled: February 19, 2021Publication date: June 10, 2021Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
-
Patent number: 10925931Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.Type: GrantFiled: January 11, 2018Date of Patent: February 23, 2021Assignee: Eli Lilly and CompanyInventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
-
Publication number: 20190231851Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.Type: ApplicationFiled: May 14, 2018Publication date: August 1, 2019Inventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
-
Patent number: 10100098Abstract: Novel proinsulins and glargine, aspart and Lis-Pro proinsulin analogs having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production, as well as novel and highly efficient processes for preparing the same. The novel proinsulins and proinsulin analogs may be converted into human insulin and insulin analogs, respectively, that are useful in therapeutic preparations.Type: GrantFiled: January 27, 2016Date of Patent: October 16, 2018Assignee: Stelis Biopharma Private LimitedInventors: Ronald E. Zimmerman, David John Stokell, Michael Patrick Akers
-
Patent number: 9993555Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.Type: GrantFiled: December 9, 2015Date of Patent: June 12, 2018Assignee: Eli Lilly and CompanyInventors: Michael Patrick Akers, Chi A. Nguyen, Chad D. Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte, Ranajoy Majumdar
-
Publication number: 20180140676Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.Type: ApplicationFiled: January 11, 2018Publication date: May 24, 2018Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
-
Patent number: 9901623Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.Type: GrantFiled: August 19, 2016Date of Patent: February 27, 2018Assignee: Eli Lilly and CompanyInventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
-
Publication number: 20170056478Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.Type: ApplicationFiled: August 19, 2016Publication date: March 2, 2017Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
-
Publication number: 20160289291Abstract: Novel proinsulins and glargine, aspart and Lis-Pro proinsulin analogs having specific amino acid and/or nucleic acid modifications suitable for improved methods of insulin production, as well as novel and highly efficient processes for preparing the same. The novel proinsulins and proinsulin analogs may be converted into human insulin and insulin analogs, respectively, that are useful in therapeutic preparations.Type: ApplicationFiled: January 27, 2016Publication date: October 6, 2016Inventors: Ronald E. ZIMMERMAN, David John STOKELL, Michael Patrick AKERS
-
Publication number: 20160166695Abstract: The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.Type: ApplicationFiled: December 9, 2015Publication date: June 16, 2016Inventors: MICHAEL PATRICK AKERS, CHI A. NGUYEN, CHAD D. PAAVOLA, VIRENDER KUMAR SARIN, NANETTE ELIZABETH SCHULTE, RANAJOY MAJUMDAR
-
Publication number: 20160030520Abstract: Disclosed herein are novel and improved preparations and methods for manufacturing substantially liquid preparations of recombinant human insulin API. The purified recombinant human insulin Active Pharamaceutical Ingredient (API) preparations are substantially free of by-products associated with the lyophilization and/or crystallization. The methods for manufacturing the substantially liquid recombinant human insulin API preparations are provided with optional steps for subjecting the recombinant insulin preparation to lyophilization and/or crystallization. Enhanced yield of recombinant insulin of greater purity are thereby provided according to the present invention. Highly purified formulations of recombinant human insulin of the API insulin preparations disclosed herein are also provided. Stably transformed E.Type: ApplicationFiled: May 5, 2015Publication date: February 4, 2016Applicant: STELIS BIOPHARMA PVT. LTD.Inventors: Ronald E. ZIMMERMAN, David John STOKELL, Michael Patrick AKERS
-
Publication number: 20120214963Abstract: Aspart modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification for producing aspart insulin analogs are provided. Highly efficient processes for preparing the aspart insulin analogs and improved preparations containing the aspart insulin analogs prepared according to the methods described herein are also provided.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: Elona BiotechnologiesInventors: Ronald E. Zimmerman, David John Stokell, Michael Patrick Akers
-
Publication number: 20120214199Abstract: Lis-Pro modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification are presented. Methods for producing Lis-Pro insulin analogs are also disclosed. Highly efficient processes for preparing the Lis-Pro insulin analogs and improved preparations containing the Lis-Pro insulin analogs prepared according to the methods described herein are also provided.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: Elona BiotechnologiesInventors: Ronald E. Zimmerman, David John Stokell, Michael Patrick Akers
-
Publication number: 20120214965Abstract: Glargine proinsulin sconstructs that have a modified C-peptide amino acid and/or nucleic acid sequence for producing glargine insulin analogs are provided. Highly efficient processes for preparing the glargine insulin analogs and improved preparations containing the glargine insulin analogs prepared according to the methods described herein are also provided.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: Elona BiotechnologiesInventors: Ronald E. Zimmerman, David John Stokell, Michael Patrick Akers
-
Publication number: 20120214964Abstract: Disclosed herein are novel and improved preparations and methods for manufacturing substantially liquid preparations of recombinant human insulin API. The purified recombinant human insulin Active Pharmaceutical Ingredient (API) preparations are substantially free of by-products associated with the lyophilization and/or crystallization. The methods for manufacturing the substantially liquid recombinant human insulin API preparations are provided with optional steps for subjecting the recombinant insulin preparation to lyophilization and/or crystallization. Enhanced yield of recombinant insulin of greater purity are thereby provided according to the present invention. Highly purified formulations of recombinant human insulin of the API insulin preparations disclosed herein are also provided. Stably transformed E. coli cell banks (WCB) capable of expressing the recombinant human insulin are also provided.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: Elona BiotechnologiesInventors: Ronald E. Zimmerman, David John Stokell, Michael Patrick Akers